Helix BioPharma Corp. is an oncology company focused on developing therapies for hard-to-treat cancers. It operates a Tumour Defence Breaker™ platform aimed at enhancing anti-tumour immunity and offers oral chemotherapy agents with bioavailability comparable to intravenous options. The company also develops immunotherapies that have established safety profiles and the potential for long-term remission in patients. Helix BioPharma serves cancer patients and operates in the biopharmaceutical sector.
- Website
- helixbiopharma.com
- Issuer profile
- All listings